CV vs PATH
CapsoVision, Inc. Common Stock (CV) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
CapsoVision, Inc. Common Stock (CV) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported CV revenue for 2025-09-30 was $3.5M. Net income was -$7.9M. Revenue was up 6.7% from 2025-06-30 to 2025-09-30. CV currently screens at market cap $359.2M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
CV currently screens at market cap $359.2M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the CV and PATH stock pages for the full models.
Not investment advice.